Cancer vaccine firm Oxford Vacmedix appoints leading global CRO to run Phase 1 trial of OVM-200

Oxford Vacmedix appoints a Global Contract Research Organisation (CRO) to run a Phase 1 trial of immunotherapy cancer vaccine OVM-200 in the UK.

Oxford, UK – 24th January 2020

Oxford Vacmedix UK Limited (OVM), the UK-based biopharma company focused on the development of cancer vaccines, announced today that a leading global CRO has been appointed to run the Phase 1 trial of lead immunotherapy cancer vaccine, OVM-200. The trial will be the first time that OVM’s novel proprietary Recombinant Overlapping Peptide (ROP) technology has been trialled in man. It will be conducted in the UK and will start later this year.

The company was selected as the CRO through a rigorous competitive tender for their experience in running Phase 1 trials, their contacts with expert Phase 1 centres in the UK and their access to analytical facilities at their UK centre. The CRO will work with OVM’s regulatory and manufacturing partners to deliver the trial, scheduled to start later in 2020. The Phase 1 trial will focus on safety and on establishing the optimal dose of OVM-200 that produces an immune response to the vaccine. The CRO will manage all aspects of the trial, to be run across several centres in the UK.

Spun out from the University of Oxford, OVM is commercialising the research led by Dr Shisong Jiang and developed in Oxford University’s Department of Oncology. The technology uses the novel, proprietary platform of recombinant overlapping peptides to design and develop therapeutic cancer vaccines and diagnostics with the potential for increased efficacy, lower costs, simpler regulatory pathways and synergy when used in combination with other IO agents. OVM has two vaccines in development, OVM-100 and OVM-200. OVM-100 is an HPV vaccine targeted at cervical cancer, and OVM-200 represents a new type of vaccine utilising survivin to target solid tumours. Both vaccines are being tested as single agents and in combination with other immune-oncology agents.

William Finch, CEO and Director at OVM, said:

“We are very pleased to have made this appointment to conduct the Phase 1 trial of OVM-200. The CRO’s experience in early Phase 1 trials will be critical to the successful delivery of the trial and we have been impressed by their approach and teamwork. We look forward to the start of the trial later in this year and to our lead cancer vaccine being progressed to this important clinical milestone, both to benefit patients and to enhance significant shareholder value”

For more information or to arrange an interview, please contact:
William Finch, CEO, Oxford Vacmedix
T: +44 (0)1865 742074 | M: +44(0)7769 903711 | E: wfinch@oxfordvacmedix.com


About Oxford Vacmedix

Oxford Vacmedix UK Ltd, based on the Oxford Science Park, UK, is a bio-pharma company that utilizes the novel proprietary platform technology of recombinant overlapping peptides (ROPs) invented by Dr Shisong Jiang. ROPs have been validated as a technology to stimulate broad and strong T cell immunity therefore forming a good platform for cancer therapeutic vaccines and diagnostics. The company is a spin-out of the University of Oxford and has extensive contacts and collaborations in China through Changzhou Bioscience (CBI) that is using the ROP platform in both diagnostics and adoptive cell therapy.

For more information, please visit: www.oxfordvacmedix.com